Industrial Policy & Trade Monitor· 2667 actions· ✨ 89 recent

USTR formally initiated the second statutorily mandated four-year review of its Section 301 investigation into China's acts, policies, and practices related to technology transfer, intellectual property, and innovation (Federal Register 2026-08806, published May 6, 2026). The review covers tariff actions imposed on approximately $300 billion of Chinese goods across Lists 1–4B (25% on most lists; 7.5% on List 4A) and will determine whether those actions should be continued, modified, or terminated. Interested parties may file continuation requests in two 60-day windows: May 7–July 5, 2026 (for the July 6, 2018 action) and June 24– August 22, 2026 (for the August 23, 2018 action). DISTINCT from the March 2026 Section 301 excess-capacity investigations (which target 16 economies on overcapacity sectors) and from the June 2026 Section 301 forced-labor enforcement action (60 economies); this review is China-specific, IP/TT-focused, and mandated by the original Biden-era statutory clock under Section 304(c) of the Trade Act of 1974.

The US Department of Commerce published its final affirmative determination of sales at less-than-fair-value in the antidumping investigation of animal feed-grade L-lysine (lysine) from China (case A-570-215) on 23 July 2026, following a preliminary determination published 6 March 2026 (91 FR 11030). Commerce found a China-wide weighted-average dumping margin of 139.83% (cash deposit rate 139.65% after subsidy-offset adjustment), based on adverse facts available after Commerce found Zhengzhou Longgu Trading Co., the sole company with a calculated margin, and the Eppen Group group of producers/exporters uncooperative and ineligible for a separate rate in the final determination. A group of separate-rate companies — including Anhui BBCA Biochemical, Heilongjiang Wanlirunda Biotechnology, and others exporting through trading intermediaries such as Agromate Sg, Ainore (Tianjin), and Aollen Biotech — received a 73.55% dumping margin (73.37% cash deposit rate). The order covers lysine regardless of form (HCl, sulfate, liquid) under HTSUS 2922.41.0090 and related subheadings. A companion countervailing-duty investigation (preliminary 22 January 2026, 91 FR 2745) was finalized the same day; suspension of liquidation runs from 6 March 2026, with a final AD order contingent on an ITC injury determination due within 45 days of the final LTFV finding.

The US Department of Commerce published its final affirmative countervailing-duty (CVD) determination on animal feed-grade L-lysine from China (case C-570-216) on 23 July 2026, the companion subsidy proceeding to the parallel antidumping case (A-570-215) finalized the same day. Commerce found Heilongjiang Wanlirunda Biotechnology Co., Ltd. and Shouguang Golden-land Industry & Trading Co., Ltd. received countervailable subsidies at 82.11%, while Inner Mongolia Eppen Biotech Co., Ltd. and all other Chinese producers/exporters were assigned a 48.21% subsidy rate. The preliminary CVD determination, published 22 January 2026, set the initial cash-deposit rates and suspension of liquidation; the final determination confirmed and aligned the case with the AD final determination for a joint ITC injury vote.

On 5 February 2026, USTR Ambassador Jamieson Greer and Argentine Foreign Minister Pablo Quirno signed in Washington the United States-Argentina Agreement on Reciprocal Trade and Investment (ARTI), formalising the framework jointly announced on 13 November 2025. The agreement is the first standalone bilateral trade-and-investment instrument concluded by the second Trump administration and the first FTA-style agreement signed under the post-IEEPA reciprocal-tariff architecture (Executive Order 14257, "Liberation Day"). On the US side, the ARTI sets out three tariff schedules: (i) Schedule 2A suspends additional reciprocal tariffs under EO 14257 for specified Argentine-origin goods (covering "unavailable natural resources" and non-patented pharmaceutical inputs); (ii) Schedule 2B grants a zero additional reciprocal tariff for designated Argentine agricultural products under EO 14360; and (iii) caps additional ad-valorem duties on other goods at 10% above MFN rates, inclusive of IEEPA reciprocal tariffs. On the Argentine side, illustrative tariff-rate quotas include duty-free access for 80,000 MT of US beef in calendar year 2026, 1,000 MT for cheese, 870 MT for almonds, 40 MT in-shell + 40 MT shelled for pistachios, 80,000 litres for wine (<2 L bottles), and preferential treatment for 10,000 motor vehicles meeting defined technical parameters. Argentina additionally commits to broader preferential market access on medicines, chemicals, machinery, information-technology products, medical devices, and a wide range of agricultural goods, alongside IP-enforcement upgrades (counterfeit/pirated-goods enforcement, patentability criteria, patent-backlog reduction, geographical indications) and investment-facilitation commitments that align Argentina's regime with US-preferred standards on regulatory cooperation, labour and environment.

The Tariff Act of 1930 (Pub. L. 71-361, 46 Stat. 590, codified principally at 19 U.S.C. Chapter 4) is the foundational US statute governing customs revenue, tariff classification, and trade-remedy administration, signed by President Hoover on 17 June 1930. The Act's original Smoot-Hawley tariff schedules are widely cited as a contributing factor to the contraction of global trade during the Great Depression, but the statute's enduring significance lies in its creation of (i) the Title VII antidumping (AD) and countervailing duty (CVD) proceedings framework administered jointly by Commerce ITA and the USITC — the parent authority for every US AD/CVD order in force today — and (ii) Section 337 (19 U.S.C. §1337), the USITC unfair-import and IP-exclusion-order regime under which ~50+ active investigations are conducted annually against semiconductor, biotech, electronics, and other technology imports. Title I's customs-valuation and HTSUS tariff- classification framework underpins all US import-revenue collection; Title VII AD/CVD authority was updated by the GATT Tokyo Round Trade Agreements Act of 1979 and the Uruguay Round Agreements Act of 1994 (URAA) to align with WTO Antidumping and Subsidies Agreements.